v3.26.1
SEGMENT INFORMATION
6 Months Ended
Jun. 30, 2026
SEGMENT INFORMATION  
SEGMENT INFORMATION

19.     SEGMENT INFORMATION

The Company reports the results of its operations as two segments in its consolidated financial statements: (i) NeuroStar, formerly known as medical device and (ii) Greenbrook, formerly known as clinic services.

The determination of its reporting segments was made based on its strategic priorities, which corresponds to the way the Company’s chief operating decision maker (“CODM”) reviews and evaluates operating performance to make decisions about resources to be allocated. For our operating segments, the CODM

uses segment gross profit and segment loss before unallocated general and administrative as the primary measure of segment performance because it reflects results that are directly attributable to each reportable segment and is the measure most consistent with the Company’s consolidated results prepared in accordance with U.S. GAAP. The CODM does not regularly review any other measures of segment profit or loss for purposes of assessing segment performance or allocating resources.

On a monthly basis, the CODM considers month-to-month and budget-to-actual variances for both measures when allocating resources to segments. The accounting policies of its segment are the same as those described in the summary of significant accounting policies. The CODM is regularly provided information on total consolidated assets and liquidity; however, the CODM is not provided asset information at the reportable segment level. Accordingly, segment assets have not been disclosed.

Significant segment expenses regularly reviewed by the CODM for both segments include directly attributable cost of revenues, selling, general and administrative and research and development expenses. Unallocated general and administrative costs include corporate support functions such as executive management, corporate accounting, information technology, legal, human resources and Board fees. Additionally, unallocated general and administrative costs may include expenses such as litigation and merger and acquisition related costs, which are not specific to a segment and thus not allocated to the reportable segments.

Segment information for prior periods has been recast to conform to the current year reportable segment structure. There were no intercompany transactions between the Company’s reportable segments during the periods presented. Reportable segment information is presented below (in thousands):

Three months ended June 30, 2026

NeuroStar

Greenbrook

Total

Revenue

$

14,677

$

26,891

$

41,568

Cost of revenues

3,312

17,033

20,345

Segment gross profit

$

11,365

$

9,858

$

21,223

Significant Segment Expense

Selling, General and Administrative

Direct

$

6,987

$

7,579

$

14,566

Research and development

Direct

1,248

88

1,336

Segment profit/(loss)

$

3,130

$

2,191

$

5,321

Unallocated expenses

General and Administrative

$

6,822

Other income, net

(162)

Interest expense

2,125

Net loss

$

(3,464)

Three months ended June 30, 2025

NeuroStar

Greenbrook

Total

Revenue

$

15,084

$

23,024

$

38,108

Cost of revenues

4,311

16,039

20,350

Segment gross profit

$

10,773

$

6,985

$

17,758

Significant Segment Expense

Selling, General and Administrative

Direct

$

8,888

$

7,331

$

16,219

Research and development

Direct

1,739

59

1,798

Segment profit/(loss)

$

146

$

(405)

$

(259)

Unallocated expenses

General and Administrative

$

7,799

Other income, net

(188)

Interest expense

1,969

Net loss

$

(9,839)

Six months ended June 30, 2026

NeuroStar

Greenbrook

Total

Revenue

$

27,602

$

48,420

$

76,022

Cost of revenues

6,170

32,475

38,645

Segment gross profit

$

21,432

$

15,945

$

37,377

Significant Segment Expense

Selling, General and Administrative

Direct

$

14,406

$

15,462

$

29,868

Research and development

Direct

2,553

148

2,701

Segment profit/(loss)

$

4,473

$

335

$

4,808

Unallocated expenses

General and Administrative

$

15,304

Other income, net

(1,182)

Loss on extinguishment of debt

539

Interest expense

4,391

Net loss

$

(14,244)

Six months ended June 30, 2025

NeuroStar

Greenbrook

Total

Revenue

$

28,400

$

41,683

$

70,083

Cost of revenues

7,461

29,126

36,587

Segment gross profit

$

20,939

$

12,557

$

33,496

Significant Segment Expense

Selling, General and Administrative

Direct

$

17,625

$

15,265

$

32,890

Research and development

Direct

3,304

110

3,414

Segment profit/(loss)

$

10

$

(2,818)

$

(2,808)

Unallocated expenses

General and Administrative

$

16,264

Other income, net

(435)

Interest expense

3,891

Net loss

$

(22,528)